Melanoma Clinical Trials

Showing 781-800 of 1,477 trials

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

NCT00130442

The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment of metastatic melanoma. PI-88 blocks new blood vessel growth in tumours (starves it of nutrients) and dacarbazine stops the cancer cells from growing. The results from this study will be analysed to see if it is worthwhile for the two drugs to be tested in future studies involving larger numbers of melanoma patients.

Melanoma

Cellxpert Biotechnology Corp.134 participantsStarted Jun 2005

Tucson, Arizona, United States • Denver, Colorado, United States • Nashville, Tennessee, United States +9 more locations

UNKNOWNNA

Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression

NCT05426317

Exploratory interventional study of prognostic serum biomarkers of cancer progression. Study of the relationship between the blood levels of soluble PDL1 and β2-microglobulin, and the clinical course of a metastatic solid tumor treated with a first-line therapeutic of checkpoint immune inhibitor.

MelanomaNon Small Cell Lung CancerRenal Cancer

University Hospital, Clermont-Ferrand100 participantsStarted Feb 2022

Clermont-Ferrand, France

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression

Related Searches

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study

Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer

Circulating Tumor Material in Colorectal Cancer and Melanoma

Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain